Catalyst Biosciences Inc (NASDAQ: CBIO) stock closed at $10.79 on 8/2/24 after a major decline of -22.8%. Moreover, this decline was accompanied by above average trading volume at 144% of normal. Relative to the market the stock has been extremely weak over the last nine months and has declined -28.0% during the last week.
Current PriceTarget Research Rating
CBIO is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment